Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial

.

Source: Human Vaccines and Immunotherapeutics - February 24, 2021 Category: Allergy & Immunology Authors: Juliana Park Sophia Archuleta May-Lin Helen Oh Lynette Pei-Chi Shek Hao Wang Matthew Bonaparte Carina Frago Alain Bouckenooghe Frederique Jantet-Blaudez Sarah Begue Sophie Gimenez-Fourage Anke Pagnon Source Type: research